Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fesoterodine Clear all

Conditions: Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
Interventions: mirabegron, antimuscarinic medication; Drug
Lead sponsor: Astellas Scientific & Medical Affairs, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 75
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 56 more

Conditions: Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
Interventions: fesoterodine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Urinary Incontinence, Urgency Urinary
Interventions: Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: fesoterodine fumarate, placebo, solifenacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bladder Outlet Obstruction
Interventions: Toviaz (Fesoterodine); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 40 Years to 99 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Overactive Bladder
Interventions: Toviaz, Premarin, Placebo cream; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 30 Years to 100 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Urge Urinary Incontinence, Overactive Bladder
Interventions: Fesoterodine, Matching Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 645 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 13
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more

Conditions: Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions: Not listed
Lead sponsor: Genelex Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more

Conditions: Urinary Bladder, Overactive
Interventions: warfarin, Warfarin plus Fesoterodine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Overactive Bladder
Interventions: Fesoterodine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 896 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 95
States / cities: Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 81 more

Conditions: Overactive Bladder Syndrome
Interventions: SPM 907; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: RTP, North Carolina

Conditions: Overactive Bladder
Interventions: Tolterodine ER, Placebo, Fesoterodine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 102
States / cities: Enterprise, Alabama • Mobile, Alabama • Montgomery, Alabama + 85 more

Conditions: Overactive Bladder
Interventions: Toviaz; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
Interventions: Fesoterodine, fesoterodine plus fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Overactive Bladder
Interventions: SPM 907; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: RTP, North Carolina

Conditions: Overactive Bladder
Interventions: Fesoterodine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 963 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 112
States / cities: Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 99 more

Conditions: Overactive Bladder
Interventions: Fesoterodine fumarate, Placebo, Percutaneous Tibial Nerve Stimulation (PTNS); Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Overactive Bladder
Interventions: fesoterodine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Treatment of Overactive Bladder
Interventions: Fesoterodine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prostate Adenocarcinoma
Interventions: Fesoterodine, Placebo oral tablet; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 30 Years to 90 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Urinary Incontinence, Bladder Dysfunction
Interventions: Fesoterodine Oral Product; Drug
Lead sponsor: Saint Thomas Health; Other
Eligibility: 21 Years to 85 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Overactive Bladder, Neurogenic Detrusor Overactivity
Interventions: Fesoterodine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Little Rock, Arkansas • Long Beach, California • Overland Park, Kansas + 5 more

Conditions: Overactive Bladder
Interventions: fesoterodine fumarate, placebo, tolterodine tartrate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 41
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 36 more

Conditions: Treatment of Overactive Bladder
Interventions: Fesoterodine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia

Premarin Versus Toviaz for Treatment of Overactive Bladder

Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)

YouScript IMPACT Registry

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

Fesoterodine Flexible Dose Study

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder

The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate

Comparative Urine Proteomic Studies of Overactive Bladder in Humans

A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients

Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects